1. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis 2023;82:351–6. doi:10.1136/ard-2022-223035.

2. Tanaka Y, O’Neill S, Li M, Tsai IC, Yang YW. Systemic lupus erythematosus: targeted literature review of the epidemiology, current treatment, and disease burden in the Asia Pacific region. Arthritis Care Res (Hoboken) 2022;74:187–98. doi:10.1002/acr.24431.

3. Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 2021;17:515-32. doi: 10.1038/s41584-021-00668-1.

4. Parodis I, Stockfelt M, Sjöwall C. B cell therapy in systemic lupus erythematosus: from rationale to clinical practice. Front Med (Lausanne) 2020;7:370. doi: 10.3389/fmed.2020.00316.

5. Giordano D, Kuley R, Draves KE, Elkon KB, Giltiay NV, Clark EA. B cell activating factor (BAFF) from dendritic cells, monocytes and neutrophils is required for B cell maturation and autoantibody production in SLE like autoimmune disease. Front Immunol 2023;14:1115967. doi: 10.3389/fimmu.2023.1050528.

6. Du SW, Jacobs HM, Arkatkar T, Rawlings DJ, Samuel WJ. Integrated B cell, toll like, and BAFF receptor signals promote autoantibody production by transitional B cells. J Immunol 2019;201: 3258–68. doi:10.4049/jimmunol.1800393.

7. Perhimpunan Reumatologi Indonesia. Rekomendasi Perhimpunan Reumatologi Indonesia: diagnosis dan pengelolaan lupus eritematosus sistemik. Jakarta: Perhimpunan Reumatologi Indonesia; 2019.

8. Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2018;32:188–205. doi:10.1016/j.berh.2018.09.004.

9. Uribe AG, Vilá LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcón GS. The systemic lupus activity measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 2004;31:1934–40.

10. Sari S, Cinar S, Yalcinkaya Y, et al. The relationship between serum A proliferation inducing ligand and B cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus. Lupus 2022;31:555–64. DOI: 10.1177/09612033221086123

11. Salazar Camarena DC, Ortiz Lazareno PC, Cruz A, et al. Association of BAFF, APRIL serum levels, BAFF R, TACI and BCMA expression on peripheral B cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus 2016;25:582–92. doi: 10.1177/0961203315608254.

12. Salazar-Camarena DC, Palafox Sánchez CA, Cruz A, Marín Rosales M, Muñoz Valle JF. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients. J Sci Rep 2020;10:6236. doi: 10.1038/s41598-020-63390-0.

13. Vincent FB, Kandane Rathnayake R, Koelmeyer R, et al. Analysis of serum B cell activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. Clin Transl Immunol 2019;8: e01062. doi: 10.1002/cti2.1047.

14. Vitri RY, Wachjudi RG, Ghassani NG, Hamijoyo L. Correlation of B cell activating factor levels and disease activity in systemic lupus erythematosus patients. Indian J Rheumatol 2021;1613–7. doi:10.4103/injr.injr_122_20.

15. Duan JH, Jiang Y, Mu H, Tang ZQ. Expression of BAFF and BR3 in patients with systemic lupus erythematosus. Braz J Med Biol Res 2016;49: e5252. doi: 10.1590/1414-431X20154853.

16. Zaki D, Ayoub NM, Mohammed ZAZ, Faramawy HH. Study of B cell activating factor (BAFF) and BAFF-R in systemic lupus erythematosus patients. Am J Med Med Sci 2019;9203–9. doi:10.5923/j.ajmms.20190906.06.

17. Zollars E, Bienkowska J, Czerkowicz J, et al. BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year. Lupus Sci Med 2015;2:e000063. doi: 10.1136/lupus-2014-000063.

18. Marín Rosales M, Cruz A, Salazar Camarena DC, et al. High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene. Clin Exp Med 2019;19:183–90. doi: 10.1007/s10238-019-00549-8.

19. Durcan L, Petri M. Why targeted therapies are necessary for systemic lupus erythematosus. Lupus 2016;25:1070–9. doi: 10.1177/0961203316652489.

20. Fanouriakis A, Kostopoulou M, Andersen J, EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2023;83:15–29. doi: 10.1136/ard-2023-224762.

21. Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D. Elevated BLyS levels in patients with systemic lupus erythematosus: associated factors and responses to belimumab. Lupus 2016;25:346–54. doi: 10.1177/0961203315604909.